Abstract
N ɛ-Nitroso-N ɛ-[N′-(2-chloroethyl)carbamoyl]-L-lysine (I) and N ɛ-[N′-(2-chloroethyl)-N′-nitrosocarbamoyl]-L-lysine (II), the isomers being the constituents of antitumor agent lysomustine, were isolated from the agent by reverse phase HPLC (RP-HPLC). The study of cytotoxicity of the above compounds against K562 cells showed that lesions induced by isomer (II) produce a significant cytotoxic effect, but can be efficiently repaired by the action of MGMT (O6-methylguanine-DNA methyltransferase). Under similar conditions, lesions induced by isomer (I) produce a substantially smaller effect but are weakly, if at all, repairable by MGMT. The effects of a clinically approved agent lysomustine, which is a mixture of isomers (I) and (II), are similar to those of isomer (II). The results obtained point to a different chemical nature of DNA lesions induced by two lysomustine isomers. Our data indicate that lysomustine and its isomer (II) can be used for in vitro selection of cells expressing MGMT.
Similar content being viewed by others
Abbreviations
- ANU:
-
alkylnitrosourea
- BG:
-
O6-benzylguanine
- CFU:
-
colony-forming unit
- BCNU:
-
1,3-bis(2-chloroethyl)-1-nitrosourea
- EGFP:
-
enhanced green fluorescent protein
- MGMT:
-
O6-methylguanine-DNA methyltransferase
- MGMTm:
-
a mutant form of MGMT
References
Emanuel’, N.M., Korman, D.B., Ostrovskaya, L.A., et al., Nitrozoalkilmocheviny — novyi klass protivoopukholevykh preparatov (Nitrozoalkyl Ureas—A New Class of Anticancer Drugs), Moscow: Nauka, 1978.
Elliott, R.D., in Cancer Chemotherapeutic Agents, Foye, W.O., Ed., Washington, DC: ACS Professional Reference Book, 1995, pp. 133–149.
Protivoopukholevaya khimioterapiya / Spravochnik (Antitumor Chemotherapy: A Handbook) Perevodchikova, N.I., Ed., Moscow: Meditsina, 1993.
Johnston, T.P., McCaleb, G.S., and Montgomery, J.A., J. Med. Chem., 1963, vol. 6, pp. 669–681.
Gnewuch, C.T. and Sosnovsky, G., Chem. Rev., 1997, vol. 97, pp. 829–1013.
Sharf, V.G., Khim.-Farm. Zh., 1989, vol. 23, no. 10, pp. 1157–1172.
Peretolchina, N.M., Radina, L.B., Gorbacheva, L.B., Shishkina, M.Ya., Mkrtchyan, T.V., Sokolova, I.A., Krasnova, M.A., Sof’ina, Z.P., Belousova, A.K., Nekrasova, E.B., Syrkin, A.B., Shulepova, T.S., Singin, A.S., Belyaev, A.A., Krasnov, V.P., Levit, G.L., Tarasov, A.I., Klyuchanskaya, N.V., Perevodchikova, N.I., Petukhova, I.N., and Zimakova, N.I., RF Patent No. 1834006, Byull. Izobret., 1996, No. 30, p. 14.
Manzyuk, L.V., Gorbunova, V.A., Kharkevich, G.Yu., and Baryshnikov, A.Yu., Eksperimental’naya onkologiya na rubezhe vekov (Experimental Oncology at the Turn of the Century), Davydov, M.I. and Baryshnikov, A.Yu., Eds., Moscow: Izdat. Gruppa RONTs im. N.M. Blokhina RAMN, 2003, pp. 179–198.
Levit, G.L., Radina, L.B., Krasnov, V.P., Gopko, V.F., Nikiforova, N.V., and Peretolchina, N.M., Khim.-Farm. Zh., 1996, vol. 30, no. 5, pp. 23–25.
Pegg, A.E., Mutat. Res., 2000, vol. 462, pp. 83–100.
Davis, B.M., Roth, J.C., Lui, L., Xu-Welliver, M., Pegg, A.E., and Gerson, S.L., Hum. Gene Therapy, 1999, vol. 10, pp. 2769–2778.
Davis, B.M., Reese, J.S., Koc, O.N., Lee, K., Schupp, J.E., and Gerson, S.L., Cancer Res., 1997, vol. 57, pp. 5093–5099.
Neff, T., Horn, P.A., Peterson, L.J., Thomasson, B.M., Thompson, J., Williams, D.A., Schmidt, M., Georges, G.E., von Kalle, C., and Kiem, H.-P., J. Clin. Invest., 2003, vol. 112, pp. 1581–1588.
Larochelle, A., Choi, U., Shou, Y., Naumann, N., Loktionova, N., Clevenger, J.R., Krouse, A., Metzger, M., Donahue, R.E., Kang, E., Stewart, C., Persons, D., Malech, H.L., Dunbar, C.E., and Sorrentino, B.P., J. Clin. Invest., 2009, vol. 119, pp. 1952–1963.
Persons, D.A., Allay, E.R., Sawai, N., Hargrove, P.W., Brent, T.P., Hanawa, H., Nienhuis, A.W., and Sorrentino, B.P., Blood, 2003, vol. 102, pp. 506–513.
Richard, E., Robert, E., Cario-Andre, M., Ged, C., Geronimi, F., Gerson, S.L., Verneuil, H., and Moreau-Gaudry, F., Gene Ther., 2004, vol. 11, pp. 1638–1647.
Sawai, N., Persons, D.A., Zhou, S., Lu, T., and Sorrentino, B.P., Mol. Ther., 2003, vol. 8, pp. 376–384.
Sorg, U.R., Kleff, V., Fanaei, S., Schumann, A., Moellmann, M., Opalka, B., Thomale, J., and Moritz, T., DNA Repair, 2007, vol. 68, pp. 197–209.
Kisby, G.E., Olivas, A., Park, T., Churchwell, M., Doerge, D., Samson, L.D., Gerson, S.L., and Turker, M.S., DNA Repair, 2009, vol. 8, pp. 400–412.
Radina, L.B., Belyaev, A.A., Krasnov, V.P., Levit, G.L., and Tarasov, A.I., RF Patent No. 1744946, Byull. Izobret., 1998, No. 32, p. 8.
Grishakov, A.N., Klochkova, T.I., Levit, G.L., Krasnov, V.P., Radina, L.B., and Chupakhin, O.N., Analitika i Kontrol’, 2001, vol. 5, no. 2, pp. 143–145.
Weber, K., Bartsch, U., Stocking, C., and Fehse, B., Mol. Ther., 2008, vol. 16, pp. 698–706.
Zvezdova, E.S., Grinenko, T.S., Pobezinskaya, E.L., Pobezinskii, L.A., and Kazanskii, D.B., Mol. Biol., 2008, vol. 42, no. 4, pp. 662–672.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © F.N. Rozov, T.S. Grinenko, G.L. Levit, A.N. Grishakov, A.V. Belyavsky, V.P. Krasnov, 2011, published in Bioorganicheskaya Khimiya, 2011, Vol. 37, No. 6, pp. 786–792.
Rights and permissions
About this article
Cite this article
Rozov, F.N., Grinenko, T.S., Levit, G.L. et al. Cytotoxicity of lysomustine and its isomers, and their potential use for selection of cells. Russ J Bioorg Chem 37, 713–718 (2011). https://doi.org/10.1134/S1068162011060112
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162011060112